Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs

Veterinary Microbiology

Volumn 154, Issue 3-4, 2012, Pages 384-394

  Gebru, Elias ^a   Damte, Dereje ^a   Choi, Myung Jin ^a   Lee, Seung Jin ^a   Kim, Young Hoan ^b   Park, Seung Chun ^a  

^a Kyungpook National University   (South Korea)

^b Gyeongbuk Veterinary Service Laboratory   (South Korea)

Author keywords

Dynamic models; E. coli; Fluoroquinolones; MPC; Resistance

Indexed keywords

DIFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ENROFLOXACIN; LEUCINE; MARBOFLOXACIN; ORBIFLOXACIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE;

ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; CODON; DOG; DRUG ACTIVITY; DRUG MEGADOSE; ESCHERICHIA COLI; GENE OVEREXPRESSION; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; MUTANT PREVENTION CONCENTRATION; NONHUMAN; PHENOTYPE; REACTION TIME; RECOMMENDED DRUG DOSE;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BASE SEQUENCE; CIPROFLOXACIN; DOG DISEASES; DOGS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION;

CANIS FAMILIARIS; ESCHERICHIA COLI;

EID: 84855963887     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2011.07.033     Document Type: Article

References (36)

1. Ball K.R., Rubin J.E., Chirino-Trejo M., Dowling P.M. Antimicrobial resistance and prevalence of canine uropathogens at the Western College of Veterinary Medicine Veterinary Teaching Hospital, 2002-2007. Can. Vet. J. 2008, 49:985-990.
2. Blaser J., Stone B.B., Zinner S.H. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob. Agents Chemother. 1985, 27:343-349.
3. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. M31-A2. CLSI (formerly NCCLS) Standards and Guidelines 2002, NCCLS, Wayne, PA.
4. Cohn L.A., Gary A.T., Fales W.H., Madsen R.W. Trends in fluoroquinolone resistance of bacteria isolated from canine urinary tracts. J. Vet. Diagn. Invest. 2003, 15:338-343.
5. Craigmill A.L., Riviere J.E., Webb A.I. Tabulation of FARAD Comparative and Veterinary Pharmacokinetic Data 2006, Blackwell Publishing, Ames, IO, pp. 719-859.
6. Dong Y., Zhao X., Kreiswirth B.N., Drlica K. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2000, 44:2581-2584.
7. Drlica K., Zhao X. Mutant selection window hypothesis updated. Clin. Infect. Dis. 2007, 44:681-688.
8. Ferran A., Dupouy V., Toutain P.L., Bousquet-Mélou A. Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin. Antimicrob. Agents Chemother. 2007, 51:4163-4166.
9. Firsov A., Sergey N., Vostrov S., Irene Y., Lubenko I., Drlica K., Portnoy Y.A., Zinner S.H. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 2003, 46:1604-1613.
10. Firsov A.A., Lubenko I.Y., Vostrov S.N., Kononenko O.V., Zinner S.H., Portnoy Y.A. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. J. Antimicrob. Chemother. 2000, 46:725-732.
11. Firsov A.A., Zinner S.H., Lubenko I.Y., Portnoy Y.A., Vostrov S.N. Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of IE over other integral parameters. Chemotherapy 2002, 48:275-279.
12. Frazier D., Thompson L.L., Trettien A., Evans E.I. Comparison of fluoroquinolone pharmacokinetic parameters after treatment with marbofloxacin, enrofloxacin, and difloxacin in dogs. J. Vet. Pharmacol. Ther. 2000, 23:293-302.
13. Friedman S., Lu T., Drlica K. Mutation in the DNA gyrase A gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob. Agents Chemother. 2001, 45:2378-2380.
14. Gebru E., Lee J.S., Chang Z.Q., Hwang M.H., Cheng H., Park S.C. Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration. Antimicrob. Agents Chemother. 2009, 53:3024-3029.
15. Gebru E., Choi M.J., Lee S.J., Damte D., Park S.C. Mutant prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli. J. Med. Microbiol. 2011, 10.1099/jmm.0. 028654-0.
16. Ihrke P.J., Papich M.G., Demanuelle T.C. The use of fluoroquinolones in veterinary dermatology. Vet. Dermatol. 1999, 10:193-204.
17. Isenberg H.D. Identification Methods: Aerobic Bacteriology. Clinical Microbiology Procedures Handbook 1995, American Society for Microbiology, Washington, DC, pp. 1.19.1-1.19.58.
18. Martinez M., McDermott P., Walker R. Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. Vet. J. 2006, 172:10-28.
19. Morgan-Linnell S.K., Zechiedrich L. Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 2007, 51:4205-4208.
20. Mueller M., de la Pena A., Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother. 2004, 48:369-377.
21. Ng E.Y., Trucksis M., Hooper D.C. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 1996, 40:1881-1888.
22. Oethinger M., Kern W.V., Jellen-Ritter A.S., McMurry L.M., Levy S.B. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob. Agents Chemother. 2000, 44:10-13.
23. Olofsson S.K., Marcusson L.L., Komp Lindgren P., Hughes D., Cars O. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J. Antimicrob. Chemother. 2006, 57:1116-1121.
24. Oram M., Fisher L.M. 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob. Agents Chemother. 1991, 35:387-389.
25. Pasquali F., Manfreda G. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa. Vet. Microbiol. 2007, 119:304-310.
26. Peterson M.L., Hovde L.B., Wright D.H., Brown G.H., Hoang D., Rotschafer J.C. Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 2002, 46:203-210.
27. Poole K. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob. Agents Chemother. 2000, 44:2233-2241.
28. Roberts J.A., Kruger P., Paterson D.L., Lipman J. Antibiotic resistance-What's dosing got to do with it?. Crit. Care Med. 2008, 36:2433-2440.
29. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J. Antimicrob. Chemother. 2003, 51:1109-1117.
30. Tejedor M.T., Martói{dotless}n J.L., Navia M., Freixes J., Vila J. Mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from canine infections. Vet. Microbiol. 2003, 94:295-301.
31. Toutain P.L., Del Castillo J.R.E., Bousquet-Mélou A. The pharmacokinetic-pharmacodynamic approach to a rational dosage-regimen for antibiotics. Res. Vet. Sci. 2002, 73:105-114.
32. Vila J., Ruiz J., Goni P., De Anta M.T. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 1996, 40:491-493.
33. Vostrov S.N., Kononenko O.V., Lubenko I.Y., Zinner S.H., Firsov A.A. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. Antimicrob. Agents Chemother. 2000, 44:879-884.
34. Walker R.D. The use of fluoroquinolones for companion animal antimicrobial therapy. Aust. Vet. J. 2000, 78:84-89.
35. Yoshida H., Bogaki M., Nakamura M., Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 1990, 34:1271-1272.
36. Zinner S.H., Lubenko I.Y., Gilbert D., Simmons K., Zhao X., Drlica K., Firsov A.A. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J. Antimicrob. Chemother. 2003, 52(570):616-622.